Summary Information:
Blueprint Medicines Corporation Common Stock
NASDAQ:BPMC


email
[email protected]
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Blueprint Medicines Corporation Common Stock
Exchange: NASDAQ
Symbol: BPMC
SEC CIK: 0001597264
Phone: 617-374-7580
45 SIDNEY STREET
CAMBRIDGE MA 02139

CEO: Jeffrey Albers
Price when page updated: 68.88 Date: 2023-11-30
Company Website:
www.blueprintmedicines.com

_Description: Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

IPO YEAR:
2015
Sector:
Health Care
Industry:
Biotechnology: Pharmaceutical Preparations
ADRTSO:

MarketCap:
4187195363.00
Beta:
1.402036617529837
52 Week High:
117.86
52 Week Low:
75.75
52 Week Change:
-0.25968198224563466
Short Interest:

Short Date:

Shares Outstanding:
58838034
Dividend Rate:
0
Dividend Yield:
N/A
ExDividend Date:

Latest EPS:

Latest EPS Date:
13 Oct 2022
Float:
0
return on Equity:
-50.60%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
N/A
ttmEPS:
-6.96
Revenue:
$18.871M
Gross Profit:

Cash:

Debt:

Institution Percent:
18.10%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
14.96%
Return on Assets:
-32.80%
Return on Capital:

Profit Margin:
-24.00%
Price to Sales:
2.87
Price To Book:
6.12
Short Ratio:
1.06
PE Ratio:
-10.862533997606224
Employees:
429
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__Blueprint Medicines Corporation Common Stock [ BPMC ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-11-30